Olivier Litzka

Olivier is a German and French citizen, and has a Ph.D. in molecular microbiology from the LMU in Munich. After his research period, he started his business career in 1998 with Mercer Management Consulting. In 2000, Olivier joined 3i Group plc with a focus on biopharma and medtech investments, first based in Munich, later in 3i’s Paris office. In 2006, Olivier joined as a partner Andera Partners’ Life Sciences team in Paris and contributed to grow the company to one of the leading Life Sciences Venture Capital investors in Europe. Since 2021, he is back in Munich where he opened an office for Andera Partners.

Olivier was on the board of multiple companies which got acquired or went public, most recently Corvidia Therapeutics and Arvelle Therapeutics. Currently, he is involved in several biotech and medtech startups in Europe and the U.S.